Alimentary Pharmacology & Therapeutics

Article	Citations
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?	135
Impact of thiopurine discontinuation at anti‐tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study	135
Editorial: natural history of hepatitis delta virus‐induced liver disease ‐ less severe today but still needs attention	133
Editorial: withdrawal of anti TNF‐alpha ‐ are we ready for biological therapy cycling?	106
Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B	98
	75
Letter: confounders and outcomes in studies of beta‐blockers in liver disease—role of PPIs?	70
Editorial: recognising the efficacy of licensed drug therapies for IBS on bloating—a step in the right direction for targeted treatment?	69
Editorial: tissue findings fail to predict disease activity or prognosis in microscopic colitis: an opportunity to look at the molecular level	66
Editorial: is there a ‘precursor’ HCC lesion and can it be detected by hepatobiliary contrast‐enhanced magnetic resonance imaging? Authors' reply	65
Issue Information	63
Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients	63
Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs—authors' reply	62
Editorial: the acid test—can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply	61
Randomised clinical trial: effects of MD‐7246 on irritable bowel syndrome with diarrhoea	61
Issue Information	60
Editorial: the acid test – can bile acids predict recurrence of Clostridioides difficile infection?	58
Editorial: ustekinumab during pregnancy—reassuring but still not enough. Authors' reply	57
Editorial: ‘Talis pater, talis filius’	55
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor‐induced colitis	55
	54
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough	52
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment	51
Review article: vascular effects of PPARs in the context of NASH	50
Editorial: the burden of alcohol‐related liver disease emergency admissions in England may be twice as high as previously thought	49

Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID‐19 pandemic: the PREPARE‐IBD multicentre cohort study	49
Editorial: Exploring the influence of diet on later‐onset ulcerative colitis—Are eggs and spicy foods the key factors in Asia? Authors' reply	49
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis	48
Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment	46
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom	46
	45
Issue Information	44
Letter: loss of response to anti‐TNFα agents in patients with inflammatory bowel disease depends on treatment duration	44
Issue Information	43
Review article: current and future treatment approaches for IBS with constipation	43
Issue Information	43
Letter: towards gender‐stratified colorectal cancer screening and surveillance? Authors’ reply	42
Editorial: cannabis use disorders at the emergency department, a sign of a growing cannabinoid emergency	41
Issue Information	41
	41
Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack?	40
Editorial: what is needed to achieve success in developing diagnostic technologies for patients with gastrointestinal motility disorders ‐ past and present. Authors' reply	40
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply	39
Editorial: first‐degree relatives of Mexican Americans with HCC are at increased risk of significant fibrosis—authors' reply	39
Editorial: what is needed to achieve success in developing diagnostic technologies for patients with gastrointestinal motility disorders ‐ past and present	39
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation	39
Issue Information	38
Editorial: Heal thyself—Autologous therapy for perianal Crohn's disease	38
Letter: association of circulating bile acid concentrations and non‐alcoholic fatty liver disease—authors’ reply	38
Editorial: serum triiodothyronine‐to‐thyroxine (T3/T4) ratio as biomarker of response in IBD ‐ an open issue	37
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply	37
Editorial: percutaneous placement of a permanent tunnelled catheter for patients with non‐malignant ascites ‐ is it safe? Authors' reply	37
Editorial: higher levels of certain serum bile acids in non‐alcoholic fatty liver disease—new insights from Guatemala	36
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis	36
Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding—authors’ reply	36
HERACLIS‐TAF: a multi‐centre prospective cohort study on 2‐year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks	36
Letter: the effect of anti‐COVID‐19 treatment on the outcome of patients with inflammatory bowel disease	36
Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis	35
Editorial: Another brick in the CDST wall	34
Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?	34
Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease	32
	32
Editorial: Has MetALD met the presumption? Authors' reply	32
Letter: Abdominal pain in inflammatory bowel disease patients in remission—A look beyond psychosocial factors	31
Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease	31
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis—Authors' reply	31
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis	31
Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection	31
Editorial: moving from the clinic towards population hepatology	30
Letter: Should metabolically healthy NAFLD also be included in the diagnostic criteria for metabolic syndrome?	30
Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here? Authorsʼ reply	30
Editorial: Alcohol‐related liver disease is the primary driver of cirrhosis‐related hospital admissions in the COVID‐19 era—What can be done?	30
Editorial: let's get physical—long‐term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease	30
Editorial: targeting liver biopsy in NAFLD – the need to expand non‐invasive tools	29
	29

	29
Editorial: risk of pneumonia in IBD—reading between the lines!	29
Letter: long‐term abdominal drains in cirrhosis – a solution or a new problem?	29
	29
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?	29
Editorial: sporadic early‐onset colorectal cancer—appreciating aetiologic complexity	28
Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction. Authors' reply	28
Editorial: total anti‐drug antibodies detected using drug‐tolerant assays during induction with anti‐TNF therapy are associated with treatment failure—out of sight but not out of mind. Authors' reply	28
Editorial: co‐morbid gastrointestinal conditions are an important consideration in IBS management	28
Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC	28
Letter: a randomised clinical trial comparing the effects of pregabalin with those of placebo on functional dyspepsia. Authors’ reply	28
Letter: faecal microbiota transplant in Clostridioides difficile infection: learning from the common water hyacinth	28
Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC—authors' reply	28
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply	27
Editorial: screening for hepatocellular carcinoma in NAFLD cirrhosis—towards abbreviated MRI alternative in patients with obesity? Authors' reply	27
Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply	27
Issue Information	27
Letter: predictive factors for treatment discontinuation in IBD—anti‐TNF trough levels and anti‐drug antibodies	27
Clinical trial: intra dermal hepatitis B vaccination with topical imiquimod versus intra muscular hepatitis B vaccination in patients with inflammatory bowel disease	27
	27
Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply	27
Letter: tofacitinib in biologic‐experienced ulcerative colitis—a single‐centre real‐world experience in Australia	27
Issue Information	26
	26
Editorial: a paradigm shift in NUDT15 assessment—towards predictive and personalised medicine in Crohn’s disease?	26
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply	26
Letter: the clinical course of Crohn’s disease—the Sicilian experience. Authors’ reply	26
Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease	25
UK guideline on the transition and management of childhood liver diseases in adulthood	25
Issue Information	25
Meta‐analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct‐acting antivirals	25
Editorial: Liver elastography for chronic hepatitis D—the end of liver biopsy?	25
Prevalence of HFE‐related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection	24
Editorial: should NAFLD be included in the definition of Metabolic Syndrome?	24
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?	24
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease	24
Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study)	24
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients	23
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases	23
Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question	23
Letter: hepatocellular carcinoma risk in patients with non‐selective beta blockers	23
Editorial: Sonographic assessment of colonic content—A new tool for constipation?	23
Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply	23
Editorial: when to start carvedilol in cirrhosis—time to reconsider? Authors' reply	23
	23
Letter: non‐invasive transabdominal stimulation device for the treatment of chronic constipation—proof‐of‐principle study in adults. Authors’ reply	23
Editorial: Retreatment of direct‐acting antiviral failures with the current first‐line regimens for patients with chronic hepatitis C	23
Clinical utility of urinary gluten immunogenic peptides in the follow‐up of patients with coeliac disease	23
Editorial: liver disease in secondary care—‘money or your life’. Authors' reply	23
Letter: association between medication use and microscopic colitis—selection of controls matters	22
Editorial: NAFLD, NAFLD, or MASLD: what's in a name?	22
	22
Editorial: Cardiometabolic criteria matters in MASLD—Authors' reply	22
Letter: Effect of dietary additives on intestinal barrier and acute stress in healthy adults	22
	22
Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis	22
Issue Information	22
Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease	22
Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D—Authors' reply	22
Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis	22
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?	22
	22
Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn’s disease—authors’ reply	22
	22
No value of non‐selective beta‐blockers after TIPS‐insertion	22
Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply	21
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IB	21
Letter: Are we forgetting the importance of steatosis in steatotic liver disease?	21
	21
Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies	21
Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet?	21
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study	21
Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy	21
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance	21
Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels	20
Editorial: proactive anti‐TNF drug monitoring in IBD—Ready for prime time?	20
Letter: Transperineal ultrasonography for ulcerative proctitis— Applicability in the pregnant population?	20
Letter: Potassium‐competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication—a retrospective multicentre‐cohort analysis. Authors' reply	20
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply	20
Editorial: If STRIDE‐II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails—Authors' reply	20

Letter: histologic disease activity and colorectal neoplasia risk—authors' reply	20
Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades – Results from a population‐based study over four decades	20
Letter: fulminant onset complicated inflammatory bowel disease (IBD) – a unique subtype? Authors' reply	20
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring—author's reply	20
Editorial: type 1 diabetes, microscopic colitis and the need to explore the complex mechanisms of this association—authors' reply	20
Editorial: suboptimal ultrasound visualisation in patients undergoing surveillance for hepatocellular carcinoma	20
Letter: diagnostic delay in inflammatory bowel disease	20
	20
Letter: 5‐aminosalicylate maintenance treatment in mild Crohn's disease—authors' reply	20
Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression	19
Editorial: autoimmune diseases in microscopic colitis—how does this information help clinicians?	19
Letter: vedolizumab or a second anti‐TNF—no difference in efficacy for primary biologic failures with IBD	19
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score	19
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination	19
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy	19
Microscopic colitis and risk of incident rheumatoid arthritis: A nationwide population‐based matched cohort study	19
Letter: enhancing training opportunities for upper GI bleeding in Sheffield ‐ a UK transferable model? Authors' reply	19
Letter: inflammatory bowel disease services during the Covid‐19 pandemic	19
Letter: tenofovir may be superior to entecavir for treatment‐naïve chronic hepatitis B patients—authors’ reply	19
Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease	19
Letter: histologic disease activity and colorectal neoplasia risk	19
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension	19
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis	19
Letter: skipping breakfast is associated with an increased long‐term cardiovascular mortality in metabolic dysfunction‐associated fatty liver disease (MAFLD) but not in MAFLD‐fre	19
Editorial: colorectal cancer in elderly‐onset IBD—what is the risk? Authors' reply	18
Editorial: is there a role for monitoring intermediate anti‐TNF drug concentrations in IBD? Authors’ reply	18
Letter: sPD‐1 as a predictor for HBsAg seroconversion—shed light on inactive carriers with chronic hepatsitis B	18
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B	18
Letter: skipping breakfast is associated with an increased long‐term cardiovascular mortality in metabolic dysfunction‐associated fatty liver disease (MAFLD) but not MAFLD‐free i	18
Editorial: refractory reflux sensitivity—A place for baclofen? Authors' reply	18
Editorial: reply to delayed gastric emptying as an independent predictor of mortality in gastroparesis—it is clinically relevant after all! Authors' reply	18
Letter: Ozanimod and latent tuberculosis	17
Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales. Authors' reply	17
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?	17
Letter: Prospective evaluation of patients with non‐cirrhotic portal hypertension—A single centre study. Authors' reply	17
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC	17
Waitlist and post‐transplant outcomes among candidates listed for liver transplant: Liver alone versus simultaneous liver kidney listings	17
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis	17
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease	17
Letter: ozanimod and latent tuberculosis—authors' reply	17
Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study	17
Editorial: Re‐evaluating early surgery in Ileocaecal Crohn's disease	17
Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?	17
Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours—Authors' reply	16
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease	16
Editorial: IBD cost evolution – transitioning from compensating lost productivity to escalating medication expenses	16
COLOFIT: Development and Internal‐External Validation of Models Using Age, Sex, Faecal Immunochemical and Blood Tests to Optimise Diagnosis of Colorectal Cancer in Symptomatic Patients	16
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch	16
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease—time for universal recommendation? Authors' reply	16
Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug. Authors' reply	16
The aging gastrointestinal tract: Epidemiology and clinical significance of disorders of gut‐brain interaction in the older general population	16
	16
	16
Continued 5ASA use after initiation of anti‐TNF or immunomodulator confers no benefit in IBD: a population‐based study	16
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o	16
Review article: Advances in the management of lower gastrointestinal bleeding	16
Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA	16
Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study	16
Editorial: HBeAg‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply	16
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted	16
Virological and Immunological Characteristics of HBeAg‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels	15
Editorial: Striving for Equitable Care in Ulcerative Colitis—Authors' Reply	15
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC	15
Letter: Reflections on the significance of myokines in alcohol‐associated liver disease	15
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome	15
Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population‐based study	15
Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study	15
Clinical trial: a controlled trial of baclofen add‐on therapy in PPI‐refractory gastro‐oesophageal reflux symptoms	15
Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled	15
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling	15
Letter: Association of Myokines With Disease Progression and Outcomes in Patients With Alcohol‐Associated Liver Disease—Authors' Reply'	15
Review Article: Rome Foundation Working Team Report: Consensus Statement on the Design and Conduct of Behavioural Clinical Trials for Disorders of Gut–Brain Interaction	15
Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply	15
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US	15
Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels	15
Letter: Metabolic Dysfunction‐Associated Steatotic Liver Disease in Primary Biliary Cholangitis—Friend, Foe or Red Herring? Authors' Reply	15
Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors	15
Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?	15
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐on‐Chronic Liver Failure. Authors' Reply	15
Non‐oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically	15
Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis	15
Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial	15
Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study	14
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep	14
Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?	14
Early ileal resection in Crohn's disease is not associated with severe long‐term outcomes: The ERIC study	14
Editorial: Is TIPSS Implantation Effective in Patients With Portal Hypertensive Gastropathy?	14
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study	14
Issue Information	14
Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply	14
Epidemiology of Helicobacter pylori	14
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?	14
Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study	14
Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD. Authors' Reply	14
Use of contraceptives and risk of inflammatory bowel disease: a nested case–control study	14